🧬 BDNF Extraction Viewer

Извлечено: 997 / 997 (100.0%) Средняя confidence: 0.13
← Назад к списку

Beta-caryophyllene restores liver-brain axis integrity in thioacetamide-induced hepatic encephalopathy: Behavioral and molecular insights.

PMID: 41654311 · DOI: 10.1016/j.neuro.2026.103400 · Neurotoxicology, 2026 · Samet Tekin, Merve Bolat, İsmail Bolat, Ömercan Alat, Burak Batuhan Laçin, Burak Çınar, Aslıhan Atasever, Mehmet Emin Ka
📄 Abstract

Hepatic encephalopathy (HE) is a severe neuropsychiatric complication of liver dysfunction, driven by hyperammonemia, oxidative stress, neuroinflammation, apoptosis, and endoplasmic reticulum (ER) stress, which disrupt the hepato-encephalic axis and impair cognition and motor functions. Despite its clinical burden, effective therapies that target this multi-organ pathology remain limited. β-Caryophyllene (BCP), an antioxidant and anti-inflammatory dietary sesquiterpene, has not been evaluated for its ability to modulate liver-brain crosstalk in HE. This study investigated the hepatoprotective and neuroprotective effects of BCP in a rat model of thioacetamide (TAA)-induced HE. Rats received TAA (200 mg/kg, i.p.) for three days, followed by BCP (100-400 mg/kg) for 14 days. A comprehensive evaluation included serum biochemistry, oxidative stress indices, inflammatory cytokines, apoptosis-related proteins, neurotrophic factors (BDNF), astroglial activation marker (GFAP), ER stress regulators (GRP78, IRE1, XBP1, PERK, CHOP, ATF6), histopathology, and behavioral outcomes. TAA caused severe hepatic and cerebral injury with elevated liver enzymes, oxidative and inflammatory mediators, ER stress dysregulation, pro-apoptotic signaling, reduced BDNF and GFAP, and impaired motor and exploratory behaviors. BCP treatment dose-dependently restored biochemical and molecular parameters, suppressed oxidative stress and neuroinflammation, normalized ER stress signaling, promoted anti-apoptotic pathways, preserved BDNF and maintained astroglial status as reflected by GFAP, and improved histoarchitecture. Importantly, moderate to high doses fully restored locomotor and exploratory activity, indicating coordinated protection across the hepato-encephalic axis. Here, for the first time, the BCP concurrently mitigates hepatic and cerebral pathology via oxidative, inflammatory, apoptotic, and ER stress pathways, supporting its translational potential as a dual hepatoprotective and neuroprotective candidate for xenobiotic-induced HE and related liver-brain disorders.

Confidence: 0.28 · 12 полей извлечено
Идентификация (6 полей)
Механизм действия (21 полей)
Mechanism
BCP acts as an antioxidant and anti-inflammatory agent, modulating oxidative stress, inflammatory cytokines, apoptosis-related proteins, and ER stress pathways.
0.90
Mutations (obesity/lean)
0.00
Activity (obesity)
0.00
Activity temporal
0.00
Energy balance
0.00
Appetite
0.00
Fat metabolism
0.00
Lipolysis
0.00
Thermogenesis
0.00
Muscle metabolism
0.00
Inflammation
BCP suppresses inflammatory mediators and neuroinflammation.
0.90
Glucose metabolism
0.00
AA metabolism
0.00
Hormonal pathways
0.00
Cell death
BCP promotes anti-apoptotic pathways and reduces pro-apoptotic signaling.
0.90
Adipocyte fibrosis
0.00
Upstream (biochem)
0.00
Upstream (physiol)
0.00
Downstream (biochem)
BCP modulates BDNF, GFAP, GRP78, IRE1, XBP1, PERK, CHOP, ATF6, and apoptosis-related proteins.
0.90
Downstream (physiol)
BCP restores locomotor and exploratory activity, and improves histoarchitecture.
0.90
PTMs
0.00
Экспрессия (8 полей)
Tissue expression
0.00
In vitro
0.00
In vivo
Rat model of thioacetamide-induced hepatic encephalopathy; rats received TAA (200 mg/kg, i.p.) for three days, followed by BCP (100-400 mg/kg) for 14 days.
0.95
In silico
0.00
Genetic association
0.00
Ex vivo
0.00
Animal model
Rat
0.95
Diet/model
Thioacetamide-induced hepatic encephalopathy
0.95
Клиника (11 полей)
Drug
Beta-caryophyllene
1.00
Indication
Hepatic encephalopathy
1.00
Patient subgroups
0.00
Safety concerns
0.00
Off-target
0.00
Trial stage
Preclinical
0.90
Pharma competitors
0.00
AE severity
0.00
MOA weight loss
0.00
Endpoints
0.00
Approved
False
0.90